Characterizing Cell Stress and GRP78 in Glioma to Enhance Tumor Treatment
Glioblastoma (GBM) is the most common primary brain tumor, carrying a very poor prognosis, with median overall survival at about 12 to 15 months despite surgical resection, chemotherapy with temozolomide (TMZ), and radiation therapy. GBM recurs in the vast majority of patients, with recurrent tumors...
Main Authors: | Kristie Liu, Kathleen Tsung, Frank J. Attenello |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.608911/full |
Similar Items
-
GRP78 in lung cancer
by: Shengkai Xia, et al.
Published: (2021-03-01) -
Metformin as Potential Therapy for High-Grade Glioma
by: Marek Mazurek, et al.
Published: (2020-01-01) -
Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management and outcomes in a series of 34 patients.
by: Christopher eDardis, et al.
Published: (2014-11-01) -
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
by: Bryan G. Harder, et al.
Published: (2019-11-01) -
ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression
by: Chen, J.-C, et al.
Published: (2023)